Seres Therapeutics, Inc.
(NASDAQ GS: MCRB)
Rigrodsky Law, P.A. is investigating Seres Therapeutics, Inc. (“Seres”) regarding possible breaches of fiduciary duties and other violations of law related to Seres’s agreement of its VOWST microbiome therapeutic business to be acquired by Societe des Produits Nestle S.A. Under the terms of the agreement, Seres shareholders will receive $1.01 per share in cash.